ECSP066408A - Heteroarilos fusionados con piridinas, pirazinas y pirimidinas, composición farmacéutica que los contiene y método para demostrar la presencia de receptores crf en muestras biológicas, útiles en el tratamiento de ansiedad y desórdenes alimenticios o - Google Patents

Heteroarilos fusionados con piridinas, pirazinas y pirimidinas, composición farmacéutica que los contiene y método para demostrar la presencia de receptores crf en muestras biológicas, útiles en el tratamiento de ansiedad y desórdenes alimenticios o

Info

Publication number
ECSP066408A
ECSP066408A EC2006006408A ECSP066408A ECSP066408A EC SP066408 A ECSP066408 A EC SP066408A EC 2006006408 A EC2006006408 A EC 2006006408A EC SP066408 A ECSP066408 A EC SP066408A EC SP066408 A ECSP066408 A EC SP066408A
Authority
EC
Ecuador
Prior art keywords
pyrazines
pyridines
useful
treatment
biological samples
Prior art date
Application number
EC2006006408A
Other languages
English (en)
Inventor
Ping Ge
Raymond F Horvath
Yan Lu Zhang
Yasuchika Yamaguchi
Bernd Kaiser
Xuechun Zhang
Suoming Zhang
He Zhao
Stanly John
Neil Moorcroft
Greg Shutske
Original Assignee
Neurogen Corp
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066408(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurogen Corp, Aventis Pharma Inc filed Critical Neurogen Corp
Publication of ECSP066408A publication Critical patent/ECSP066408A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos heteroarilo fusionados con piridinas, pirazinas y pirimidinas de fórmulas I-a, I-b, XX, I-a I-b XXdonde Z1, Z2, Z3, Z4, Z5, E, Ar y R son como se define en la memoria descriptiva, útiles en el tratamiento de diveros desórdenes periféricos del sistema nervioso central, particularmente estrés, ansiedad, depresió, desórdenes cardiovasculares y desordenes alimentarios; composiciones farmacéuticas que los contienen; y métodos para ensayar la localización de CRF en muestras biológicas.
EC2006006408A 2003-09-05 2006-03-03 Heteroarilos fusionados con piridinas, pirazinas y pirimidinas, composición farmacéutica que los contiene y método para demostrar la presencia de receptores crf en muestras biológicas, útiles en el tratamiento de ansiedad y desórdenes alimenticios o ECSP066408A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50041403P 2003-09-05 2003-09-05

Publications (1)

Publication Number Publication Date
ECSP066408A true ECSP066408A (es) 2006-09-18

Family

ID=34272952

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006408A ECSP066408A (es) 2003-09-05 2006-03-03 Heteroarilos fusionados con piridinas, pirazinas y pirimidinas, composición farmacéutica que los contiene y método para demostrar la presencia de receptores crf en muestras biológicas, útiles en el tratamiento de ansiedad y desórdenes alimenticios o

Country Status (19)

Country Link
US (2) US20050113379A1 (es)
EP (1) EP1680424A2 (es)
JP (1) JP2007504271A (es)
KR (1) KR20060088534A (es)
CN (1) CN1878773A (es)
AP (1) AP2006003559A0 (es)
AR (1) AR045582A1 (es)
AU (1) AU2004270713A1 (es)
BR (1) BRPI0414087A (es)
CA (1) CA2537829A1 (es)
CR (1) CR8274A (es)
EA (1) EA200600372A1 (es)
EC (1) ECSP066408A (es)
IL (1) IL174084A0 (es)
MA (1) MA28086A1 (es)
NO (1) NO20061180L (es)
TW (1) TW200530232A (es)
WO (1) WO2005023806A2 (es)
ZA (1) ZA200601978B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504243A (ja) * 2003-09-03 2007-03-01 ニューロジェン・コーポレーション ５−アリール−ピラゾロ［４，３−ｄ］ピリミジン類、ピリジン類、ピラジン類及び関連化合物
CN103467471A (zh) 2005-06-06 2013-12-25 武田药品工业株式会社 有机化合物
JP2009506006A (ja) 2005-08-25 2009-02-12 エフ．ホフマン−ラ ロシュ アーゲー ｐ３８ＭＡＰキナーゼ阻害剤およびその使用方法
US8143285B2 (en) 2005-09-06 2012-03-27 Shionogi & Co., Ltd. Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity
US7405302B2 (en) * 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
ZA200803887B (en) 2005-11-08 2009-12-30 Vertex Pharma Heterocyclic modulators of ATP-Binding Cassette transporters
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
US20100184771A1 (en) 2005-12-15 2010-07-22 Ono Pharmaceutical Co., Ltd. Bicyclic Heterocyclic Compound
TW200812588A (en) * 2006-05-15 2008-03-16 Neurogen Corp CRF1 receptor ligands comprising heteroaryl fused bicycles
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
JP5837278B2 (ja) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
WO2008076446A1 (en) * 2006-12-18 2008-06-26 Coleman Peter R Accelerated opiate dependence detoxification process
CN101558072A (zh) 2006-12-19 2009-10-14 霍夫曼-拉罗奇有限公司 吡唑并[3,4-d]嘧啶p38map激酶抑制剂
WO2008083070A1 (en) * 2006-12-29 2008-07-10 Neurogen Corporation Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties
NZ581259A (en) 2007-05-09 2012-07-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
CN101969774A (zh) * 2007-12-06 2011-02-09 细胞内治疗公司 有机化合物
EP2639223B1 (en) 2007-12-07 2017-03-29 Vertex Pharmaceuticals Incorporated Process for producing cycloalkylcarboxiamido-pyridine benzoic acids
CA2986286C (en) 2007-12-07 2019-04-23 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
JP5523352B2 (ja) 2008-02-28 2014-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒ修飾因子としてのへテロアリール誘導体
EP2285803A4 (en) 2008-05-23 2011-10-05 Amira Pharmaceuticals Inc Inhibitor of 5-Lipoxygenase Activating Protein
DK2331547T3 (da) 2008-08-22 2014-11-03 Novartis Ag Pyrrolopyrimidinforbindelser som CDK-inhibitorer
KR20110098730A (ko) 2008-12-06 2011-09-01 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
EP2367430B1 (en) 2008-12-06 2014-08-13 Intra-Cellular Therapies, Inc. Organic compounds
PE20110922A1 (es) 2008-12-06 2012-01-22 Intra Cellular Therapies Inc DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1)
US8697710B2 (en) 2008-12-06 2014-04-15 Intra-Cellular Therapies, Inc. Optionally substituted 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo [3,4-d]pyrimidin-6(7H)-ones
MA32942B1 (fr) 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
CN102238872A (zh) * 2008-12-06 2011-11-09 细胞内治疗公司 有机化合物
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2010096426A2 (en) * 2009-02-20 2010-08-26 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
EP2434895A4 (en) 2009-05-13 2013-08-07 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US20120295942A1 (en) 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
CA2795804C (en) 2010-04-07 2021-10-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
EP2590657A4 (en) 2010-05-31 2014-02-12 Intra Cellular Therapies Inc ORGANIC COMPOUNDS
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
JP5911854B2 (ja) 2010-05-31 2016-04-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP5879336B2 (ja) 2010-05-31 2016-03-08 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
PE20140245A1 (es) 2010-10-08 2014-03-30 Abbvie Inc Compuesto de furo[3,2-d]pirimidina
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
WO2013131923A1 (de) * 2012-03-06 2013-09-12 Bayer Intellectual Property Gmbh Substituierte azabicyclen und ihre verwendung
SG11201405810UA (en) 2012-05-03 2014-11-27 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
EP2968338B1 (en) 2013-03-15 2019-01-09 Intra-Cellular Therapies, Inc. Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
RU2679142C2 (ru) 2013-03-15 2019-02-06 Интра-Селлулар Терапиз, Инк. Органические соединения
CN105848657B (zh) 2013-11-12 2020-05-22 沃泰克斯药物股份有限公司 制备用于治疗cftr介导的疾病的药物组合物的方法
SI3102576T1 (sl) 2014-02-03 2019-08-30 Vitae Pharmaceuticals, Llc Inhibitorji dihidropirolopiridina ROR-gama
EP2940022B1 (en) * 2014-04-30 2020-09-02 Masarykova Univerzita Furopyridines as inhibitors of protein kinases
US9884872B2 (en) 2014-06-20 2018-02-06 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
EP3177627B1 (en) 2014-08-07 2019-07-24 Intra-Cellular Therapies, Inc. Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-one derivatives with pde1 inhibiting activity
BR112017005533B1 (pt) 2014-09-17 2023-10-10 Intra-Cellular Therapies, Inc Compostos inibidores de fosfodiesterase 1 (pde1), composição farmacêutica que compreende os ditos compostos e usos dos mesmos no tratamento de uma doença, distúrbio, e/ou lesão do snc e no tratamento e/ou na profilaxia de uma doença, distúrbio e/ou lesão do snp
BR112017007460A2 (pt) 2014-10-14 2017-12-19 Vitae Pharmaceuticals Inc inibidores de di-hidropirrolopiridina de ror-gama
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
DK3221692T3 (da) 2014-11-18 2021-08-23 Vertex Pharma Fremgangsmåde til udførsel af tests med høj kapacitet ved hjælp af højtryksvæskekromatografi
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
WO2017087608A1 (en) 2015-11-20 2017-05-26 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3510029A4 (en) * 2016-09-07 2020-03-11 The Regents of The University of California ALLOSTERIC CORTICOTROPIN RELEASING FACTOR-1 (CRFR1) ANTAGONISTS TO REDUCE P-TAU AND IMPROVE THE COGNITION
JP7134168B6 (ja) 2016-09-12 2024-02-02 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
KR20200053481A (ko) 2017-07-24 2020-05-18 비타이 파마슈티컬즈, 엘엘씨 RORγ의 억제제
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
EP3746081A4 (en) 2018-01-31 2021-10-27 Intra-Cellular Therapies, Inc. INNOVATIVE USES
CN110437846B (zh) * 2019-08-30 2022-02-25 陕西师范大学 含炔键的氟取代苯并噁唑液晶化合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3398152B2 (ja) * 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
JPH10506126A (ja) * 1995-05-12 1998-06-16 ニューロゲン コーポレイション 新規なデアザプリン誘導体；ｃｒｆ１特異性リガンドの新規なクラス
JP3964478B2 (ja) * 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
DE69736711T2 (de) * 1996-08-28 2007-09-20 Pfizer Inc. Substituierte 6,5-heterobicyclische-derivate
US6310063B1 (en) * 1998-04-02 2001-10-30 Neurogen Corporation Aminoalkyl substituted pyrrolo [3,2-E]pyridine and pyrollo [2,3-b]pyrimidine derivatives: modulators of CRF1 receptors
US6828329B2 (en) * 2000-06-26 2004-12-07 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
DE10229777A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
CN1809351A (zh) * 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂

Also Published As

Publication number Publication date
EA200600372A1 (ru) 2006-08-25
WO2005023806A2 (en) 2005-03-17
CR8274A (es) 2008-06-10
AP2006003559A0 (en) 2006-04-30
WO2005023806A3 (en) 2005-06-02
EP1680424A2 (en) 2006-07-19
CA2537829A1 (en) 2005-03-17
JP2007504271A (ja) 2007-03-01
BRPI0414087A (pt) 2006-10-31
NO20061180L (no) 2006-03-31
AR045582A1 (es) 2005-11-02
MA28086A1 (fr) 2006-08-01
AU2004270713A1 (en) 2005-03-17
US20060199823A1 (en) 2006-09-07
KR20060088534A (ko) 2006-08-04
IL174084A0 (en) 2008-02-09
ZA200601978B (en) 2007-05-30
TW200530232A (en) 2005-09-16
US20050113379A1 (en) 2005-05-26
CN1878773A (zh) 2006-12-13

Similar Documents

Publication Publication Date Title
ECSP066408A (es) Heteroarilos fusionados con piridinas, pirazinas y pirimidinas, composición farmacéutica que los contiene y método para demostrar la presencia de receptores crf en muestras biológicas, útiles en el tratamiento de ansiedad y desórdenes alimenticios o
EA201170769A1 (ru) Органические соединения
CL2009000943A1 (es) Metodos de preparacion de compuestos intermediarios del tipo pirazoles condensados para la preparacion de moduladores de los receptores de serotonina. (divisional solicitud n° 2384-04)
CR8718A (es) Compuesto de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central
HK1117532A1 (en) Novel deuterated benzo [d][1,3]-dioxol derivatives as serotonin reuptake inhibitors
TW200503705A (en) 3-amino chroman and 2-amino tetralin derivatives
DE602006007556D1 (de) Heteroarylsulfonylstilbene als 5-ht2a-antagonisten
BRPI0513475A (pt) derivados quinazolin-4-il-piperidina e cinolin-4-il-piperidina como inibidores de pde10 no tratamento de distúrbios do snc
EA200702347A1 (ru) Способ получения глюкопиранозилзамещённых производных бензилбензола и промежуточных продуктов для их получения
UY28970A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos
CY1109568T1 (el) Ενωσεις βενζο(d)ισοξαζολ-3-υλαμινης και η χρησιμοποιηση τους σαν προσδεματα υποδοχεα βανιλλοειδων
EA200601279A1 (ru) Пиперидинилкарбонилпирролидины и их применение в качестве агонистов меланокортина
UY29324A1 (es) Compuestos de quinolina heteroaromrticos
AR091405A2 (es) Omega-carboxiaril difenil urea sustituida con fluoro y composiciones farmaceuticas que las contienen
HRP20050933A2 (en) Organic compounds
EA201100877A1 (ru) Спирогетероциклические n-оксиамиды в качестве пестицидов
CO6331473A2 (es) Derivados de 2,3-dihidrobenzo[1,4]dioxin-2-ilmetilo como antagonistas alfa2c para uso en el tratamiento de enfermedades del sistema nervioso central y periferico
DE602006006170D1 (de) Phenylacetylenderivate mit affinität zum mglur5-rezeptor
EA200970519A1 (ru) Полиморфы сукцината 2-[6-(3-аминопиперидин-1-ил)-3-метил-2,4-диоксо-3,4-дигидро-2h-пиримидин-1-илметил]-4-фторбензонитрил и способы их применения
EA201170768A1 (ru) Органические соединения
ATE441646T1 (de) 5-ht4-rezeptoragonistenverbindungen
ATE431824T1 (de) Chinolinon-carboxamid-verbindungen
TW200800959A (en) Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
ES2335410T8 (es) Derivados de aminopropanol.
EA200970472A1 (ru) Замещенные пиразолы, композиции, их содержащие, способ получения и применение